Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 28, 2014; 20(48): 18452-18457
Published online Dec 28, 2014. doi: 10.3748/wjg.v20.i48.18452
Published online Dec 28, 2014. doi: 10.3748/wjg.v20.i48.18452
Table 3 Drug administration
| Unresectable(n = 55) | Recurrent(n = 10) | P value | |
| Treatment cycle | |||
| Median, range | 4 (1-26) | 7.5 (1-23) | 0.15 |
| Dose intensity (overall) | |||
| Gemcitabine | 96.8% | 83.5% | < 0.01 |
| S-1 | 91.8% | 75.9% | < 0.01 |
| Dose intensity (first two cycles) | |||
| Gemcitabine | 95.3% | 89.4% | 0.13 |
| S-1 | 90.7% | 78.9% | 0.04 |
- Citation: Sasaki T, Isayama H, Nakai Y, Ito Y, Yasuda I, Toda N, Yagioka H, Matsubara S, Hanada K, Maguchi H, Kamada H, Hasebe O, Mukai T, Okabe Y, Maetani I, Koike K. Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer. World J Gastroenterol 2014; 20(48): 18452-18457
- URL: https://www.wjgnet.com/1007-9327/full/v20/i48/18452.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i48.18452